MedTrace Logo

Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors

NCT02691078 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-02-04

No results posted yet for this study

Summary

Evaluation of the properties of the image capture test using 99m Tc - HYNIC -TOC EDDA (octreotide labeled with 99mTc) for the diagnosis of neuroendocrine tumors compared to the 111In - DTPA-octreotide.

Conditions

Interventions

OTHER

99m Tc - HYNIC -TOC EDDA and 111In - DTPA-octreotide

The patient will undercome an PET/CT exam with 99m Tc - HYNIC -TOC EDDA, after 20 days of wash out, the same patient will undercome the same exam with 111In - DTPA-octreotide in order to compare both radiopharmaceuticals

Sponsors & Collaborators

  • Financiadora de Estudos e Projetos

    collaborator OTHER

  • Instituto do Cérebro do Rio Grande do Sul - InsCer

    collaborator UNKNOWN

  • Latin American Cooperative Oncology Group

    lead OTHER

Principal Investigators

  • Gustavo Werutsky, MD · Latin American Cooperative Oncology Group

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2018-01-31
Completion
2018-01-10

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02691078 on ClinicalTrials.gov